# CD30 CAR-T for multiply relapsed Hodgkin lymphoma

Source: https://onco.cc/ideas/idea-cd30-car-t-hodgkin/  
OnCo record `idea-cd30-car-t-hodgkin` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Engineer T cells against CD30 for the few patients who fail brentuximab, PD-1 blockade and transplant.

## Summary

For the few patients with Hodgkin lymphoma who relapse after brentuximab vedotin, PD-1 blockade and transplant, this idea proposes CAR-T cells engineered against CD30. CD30 is expressed on nearly all Reed-Sternberg cells, shed CD30 does not block binding at therapeutic doses, and the inflamed microenvironment supports CAR-T trafficking. Phase 1/2 studies at UNC and Baylor and of the Tessa Therapeutics TT11 product produced responses and complete remissions in a substantial share of patients, although durability was modest, and the pivotal CHARIOT study was halted for business reasons in 2023 to 2024. The hypothesis is that CD30 CAR-T after PD-1 failure yields durable remissions and that PD-1 blockade prolongs persistence, tested in a randomised phase 2, at an early clinical stage.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: CD30 CAR-T after PD-1 failure yields durable CR in ≥40% of patients with an acceptable CRS profile, and combination with PD-1 blockade prolongs persistence.
- Rationale: CD30 is near-universal on Reed-Sternberg cells and shed CD30 does not block binding at therapeutic doses; the inflamed microenvironment supports CAR-T trafficking.
- Proposed test: Randomised phase 2 of CD30 CAR-T ± nivolumab vs investigator's choice in triple-refractory disease.
- Maturity: early-clinical

## Sources

- Ramos et al., Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma (Journal of Clinical Oncology 2020): https://doi.org/10.1200/JCO.20.01342

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD30](https://onco.cc/targets/cd30/)
- key papers: [Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma](https://onco.cc/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/), [Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project](https://onco.cc/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/), [Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions](https://onco.cc/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-cd30-car-t-hodgkin.json